I

    INmune Bio Inc (INMB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.30
    -0.03 (-1.29%)

    Market Cap: $64.67M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    58%(18/31)
    Avg Surprise
    -53.93%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.18
    Range$-0.20 - $-0.17
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.17+10.8%
    60d ago$-0.17+10.8%
    30d ago$-0.17+10.8%
    7d ago$-0.18+0.0%
    Current$-0.18
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Dec 31, 2026
    EPS Consensus$0.01
    Range$-0.10 - $0.14
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.01---
    Sep 26EST
    		-$-0.18---
    Jun 26
    		$-0.05N/A+75.00%Beat+85.3%
    Mar 26
    		$-0.20$-0.18-11.11%Miss+53.5%
    Dec 25
    		$-0.18$-0.27+33.33%Beat+55.0%
    Sep 25
    		$-0.24$-0.32+25.00%Beat+60.0%
    Jun 25
    		$-0.34$-0.37+8.11%Beat+32.0%
    Mar 25
    		$-0.43$-0.45+4.44%Beat+29.5%
    Dec 24
    		$-0.40$-0.54+25.93%Beat+14.9%
    Sep 24
    		$-0.60$-0.49-22.45%Miss-25.0%
    Jun 24
    		$-0.50$-0.62+19.35%Beat-38.9%
    Mar 24
    		$-0.61$-0.52-17.31%Miss-69.4%
    Dec 23
    		$-0.47$-0.44-6.82%Miss-46.9%
    Sep 23
    		$-0.48$-0.40-20.00%Miss-11.6%
    Jun 23
    		$-0.36$-0.38+5.26%Beat+5.3%
    Mar 23
    		$-0.36$-0.02-1700.00%Miss+7.7%
    Dec 22
    		$-0.32$-0.48+33.33%Beat+41.8%
    Sep 22
    		$-0.43$-0.52+17.31%Beat+21.8%
    Jun 22
    		$-0.38$-0.47+19.15%Beat+13.6%
    Mar 22
    		$-0.39$-0.60+35.00%Beat-21.9%
    Dec 21
    		$-0.55$-0.58+5.17%Beat-111.5%
    Sep 21
    		$-0.55$-0.40-37.50%Miss-52.8%
    Jun 21
    		$-0.44$-0.34-29.41%Miss-120.0%
    Mar 21
    		$-0.32$-0.28-14.29%Miss-68.4%
    Dec 20
    		$-0.26$-0.31+16.13%Beat-18.2%
    Sep 20
    		$-0.36$-0.17-111.76%Miss-28.6%
    Jun 20
    		$-0.20$-0.23+13.04%Beat-5.3%
    Mar 20
    		$-0.19$-0.21+9.52%Beat+5.0%
    Dec 19
    		$-0.22$-0.25+12.00%Beat-4.8%
    Sep 19
    		$-0.28$-0.19-47.37%Miss-600.0%
    Jun 19
    		$-0.19$-0.20+5.00%Beat+65.5%
    Mar 19
    		$-0.20$-0.19-5.26%Miss+20.0%
    Dec 18
    		$-0.21$-0.19-10.53%Miss-600.0%
    Sep 18
    		$-0.04$0.00N/AMiss-
    Jun 18
    		$-0.55$0.00N/AMiss-
    Mar 18
    		$-0.25$0.00N/AMiss-
    Sep 17
    		$-0.03$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.43EV/EBITDA-5.31x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-74.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio4.04xQuick Ratio4.04x
    Trading Statistics
    Beta0.90Avg Volume385.82K
    52-Week High$2.5052-Week Low$1.09

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.31
    SMA 20$2.18
    SMA 50$1.91
    SMA 200$1.58
    EMA 10$2.30
    EMA 20$2.19
    EMA 50$1.96
    EMA 200$2.01

    MACD

    Line: 0.14Signal: 0.14Hist: 0.00

    ADX

    ADX: 37.4+DI: 26.3-DI: 15.9

    Aroon & PSAR

    Aroon Up88.0
    Aroon DownN/A
    PSAR$2.21

    Bollinger Bands

    Upper Band$2.52
    Lower Band$1.83
    %B Position3147%(Upper)
    Band Width0.68

    RSI (14-Day)

    Neutral
    61.1

    Momentum Oscillators

    Stoch %K68.2
    Stoch %D78.1
    Williams %R-40.7
    ROC (10d)8.0%
    Momentum0.17
    CCI (20d)51.2
    MFI (14d)63.4

    Volatility Measures

    ATR (14d)$0.13(5.7%)
    StdDev (20d)0.17
    Hist Vol55.0%(High)

    Volume Flow

    VWAP$2.28
    OBV-56.2M
    AD Line-31.9M
    CMF (20d)0.161

    Volume Metrics

    Avg Vol (20d)394.0K
    Vol Ratio0.7x
    VWMA (20d)$2.17

    Pivot Points

    R3$2.57
    R2$2.51
    R1$2.42
    Pivot Point$2.36
    S1$2.27
    S2$2.21
    S3$2.12

    Advanced Oscillators

    TSI31.58
    Ultimate Osc53.7
    KST246.58

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$50,000$0$0$0$14,000$28,000$43,000
    Cost of Revenue$0$0$56,000$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0$-56,000$0$0$50,000N/A$0$0$14,000$28,000$43,000
    Operating Expenses$1.48M$5.81M$5.47M$7.43M$24.57M$9.96M$9.47M$12.29M$9.87M$11.03M$8.41M$8.57M
    R&D$-803,000$3.64M$2.33M$4.89M$5.80M$7.64M$7.35M$10.07M$7.05M$8.69M$6.01M$5.99M
    SG&A$2.28M$2.17M$3.15M$2.55M$2.25M$2.32M$2.11M$2.22M$2.81M$2.34M$2.40M$2.59M
    Operating Income$-1,476,000$-5,812,000$-5,474,000$-7,433,000$-24,571,000$-9,905,000$-9,467,000$-12,286,000$-9,865,000$-11,017,000$-8,379,000$-8,528,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$8,000$29,000$35,000
    Income Before Tax$-1,273,000$-5,407,000$-5,264,000$-6,472,000$-24,458,000$-9,739,000$-9,218,000$-12,093,000$-9,746,000$-11,025,000$-8,408,000$-8,563,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,273,000$-5,407,000$-5,264,000$-6,472,000$-24,458,000$-9,739,000$-9,218,000$-12,093,000$-9,746,000$-11,025,000$-8,408,000$-8,563,000
    EBITDA$-1,207,000$-5,760,000$-5,418,000$-7,433,000$-24,458,000$-9,905,000$-9,461,000$-12,271,000$-9,841,000$-10,991,000$-8,334,000$-8,474,000
    EBIT$-1,273,000$-5,812,000$-5,474,000$-7,433,000$-24,458,000$-9,905,000$-9,467,000$-12,286,000$-9,865,000$-11,025,000$-8,379,000$-8,528,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INMB

    News

    Inmune Stock Price Forecast. Should You Buy INMB?

    StockInvest.us rates Inmune (INMB) as a Buy Candidate with a technical score of 4.78, indicating strong positive signals. The stock price gained 4.33% on the last trading day, and a further rise of 51.46% is predicted over the next three months. Several short-term and long-term buy signals, along with increased trading volume, suggest a good buying opportunity.

    StockInvest.us•8/15/26•
    Bullish

    INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates

    INmune Bio Inc (INMB) currently holds an earnings forecast score of 8.00 within the Biotechnology & Medical Research industry, ranking 170 out of 387. Analysts have set an average price target of $7.00 for INMB, with individual forecasts ranging from $2.00 to $21.00, suggesting a potential upside of 268.66%. The company's stock has a "Buy" rating based on the consensus of 4 analysts.

    TradingKey•8/14/26•
    Bullish

    INmune Bio (NASDAQ:INMB) Upgraded by Wall Street Zen to "Hold" Rating

    Wall Street Zen has upgraded INmune Bio (NASDAQ:INMB) from a "Sell" to a "Hold" rating, though Weiss Ratings simultaneously downgraded it from "Sell (D-)" to "Sell (E+)." Despite this mixed sentiment, MarketBeat's overall analyst consensus for INmune Bio remains a "Moderate Buy." The company, a clinical-stage immunology firm, exceeded its recent earnings estimates, reporting a loss of $0.05 per share against a consensus of $0.21.

    MarketBeat•8/8/26•
    Neutral

    Press Release: INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

    INmune Bio Inc. announced its second-quarter 2026 financial results, highlighting significant progress in its regulatory filings, manufacturing capabilities, and ongoing clinical trials. The company is advancing its pipeline with key developments in its drug candidates, reflecting a productive period for research and development. This update provides stakeholders with insights into the company's operational performance and strategic advancements during the quarter.

    Moomoo•8/7/26•
    Somewhat-Bullish

    INmune Bio, Inc. Q2 2026 Earnings Call Summary

    INmune Bio, Inc. reported its Q2 2026 earnings, highlighting significant progress in its regulatory and commercial readiness for Ebstracel, including MHRA alignment and pediatric investigation plan approval. The company also confirmed a disciplined capital allocation strategy with a cash runway into Q2 2027 and a reduced net loss. Key developments include plans for MAA/BLA submissions, a Phase 3 confirmatory trial for Ebstracel, and evaluation of strategic partnerships for its XPro platform.

    Yahoo Finance•8/7/26•
    Neutral

    Frequently Asked Questions About INMB

    Does INMB pay dividends?
    INmune Bio Inc (INMB) does not currently pay a regular dividend.
    What is INMB's market cap?
    INmune Bio Inc (INMB) has a market capitalization of $64.67M with a current stock price of $2.30.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In